膀胱癌中的PET/CT:进展更新
膀胱癌是泌尿系统最常见的恶性肿瘤,约30%为肌层浸润性膀胱癌且远处转移风险高,70%为浅表性肿瘤倾向复发但通常不致命。本综述更新了PET/CT在膀胱癌中的应用,指出FDG PET/CT越来越多用于肌层浸润性膀胱癌的初始分期和根治性膀胱切除术后复发检测,少数研究用于新辅助、诱导化疗或免疫治疗的反应评估,小样本研究测试了尿液排泄少的非FDG PET显像剂。
要点
- FDG PET/CT越来越多用于肌层浸润性膀胱癌初始分期及根治性膀胱切除术后复发检测。
- 少数研究将FDG PET/CT用于新辅助、诱导化疗或免疫治疗的反应评估。
- 小样本研究测试了尿液排泄少或无排泄的非FDG PET显像剂。
核心结论
- 本综述提供了PET/CT在膀胱癌中应用的进展更新,FDG PET/CT在肌层浸润性膀胱癌初始分期和根治性膀胱切除术后复发检测中的应用日益增多。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 约30%的膀胱癌患者表现为肌层浸润性膀胱癌,远处转移风险高且与远处转移死亡风险相关。
- 其余70%的膀胱癌患者表现为浅表性肿瘤,有复发倾向但总体不致命。
- FDG PET/CT越来越多用于肌层浸润性膀胱癌的初始分期和根治性膀胱切除术后复发检测。
- 少数研究使用FDG PET/CT进行新辅助、诱导化疗或免疫治疗的反应评估。
- 小样本研究测试了尿液排泄少或无排泄的非FDG PET显像剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the urinary tract, bladder cancer is the most common malignancy. It is a heterogenous cancer type with approximately 30% presenting as muscle invasive bladder cancer with a high risk of metastatic spread associated with risk of death from distant metastases. The other 70% of bladder cancer patients present with superficial tumors with tendency of recurrence but in general not life-threatening. Like in other malignancies, accurate and precise staging of bladder cancer is one of the mainstays at the time of diagnosis to select the optimal treatment for each patient. The detection of metastatic spread is of utmost importance for selection of treatment strategy. Hybrid imaging med with FDG PET/CT is widely used in the clinical management of a variety of malignancies. FDG PET/CT is increasingly used for primary staging of muscle invasive bladder cancer and for detection of recurrence after radical cystectomy. Few studies have used FDG PET/CT for response evaluation of neoadjuvant, induction chemotherapy or immunotherapy. Furthermore, small studies have tested non-FDG PET agents with little or no urinary excretions of the tracer. This review provides an update on PET/CT in bladder cancer.
引用
- Bouchelouche K. PET/CT in Bladder Cancer: An Update. Semin Nucl Med. 2022. PMID: 34996595. doi:10.1053/j.semnuclmed.2021.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。